Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
7.103
Zitationen
15
Autoren
2016
Jahr
Abstract
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).
Ähnliche Arbeiten
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
1985 · 31.163 Zit.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
1998 · 19.978 Zit.
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation
1998 · 15.216 Zit.
International Diabetes Federation 2017
2018 · 13.550 Zit.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 · 11.737 Zit.
Autoren
Institutionen
- The University of Texas Southwestern Medical Center(US)
- Massachusetts General Hospital(US)
- Novo Nordisk (Denmark)(DK)
- Friedrich-Alexander-Universität Erlangen-Nürnberg(DE)
- Ruhr University Bochum(DE)
- St. Josef-Hospital(DE)
- Cleveland Clinic London(GB)
- London School of Hygiene & Tropical Medicine(GB)
- Imperial College London(GB)
- George Washington University(US)
- Washington University Medical Center(US)
- Sinai Hospital(US)
- Lunenfeld-Tanenbaum Research Institute(CA)
- University of Toronto(CA)
- Park Nicollet Clinic(US)
- University of North Carolina at Chapel Hill(US)